SciSparc Ltd. (SPRC) Balance Sheet

The consistent downward trend in total assets suggests that the company is consuming its capital reserves faster than it can replenish them through commercial activities or financing. This trajectory indicates a weakening balance sheet that may limit the firm's ability to sustain long-term clinical development without further dilutive capital raises.

While a current ratio of 2.41 may appear adequate on the surface, the absolute cash balance of $4.6M against a history of heavy operating losses suggests a precarious liquidity position. Investors should monitor the burn rate closely, as the current cash buffer may be insufficient to support the company's multi-indication clinical trial strategy through the next fiscal year.

The deep negative retained earnings balance indicates that the company has consistently failed to generate profitable growth, forcing a reliance on equity financing that likely results in significant shareholder dilution. This trend suggests that the equity base is primarily a function of past capital injections rather than value creation from core operations.